Patents by Inventor Peter Boderke

Peter Boderke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ZINC-FREE AND LOW-ZINC INSULIN PREPARATIONS HAVING IMPROVED STABILITY
    Publication number: 20070155653
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Application
    Filed: March 8, 2007
    Publication date: July 5, 2007
    Inventor: Peter Boderke
  • Zinc-free and low-zinc insulin preparations having improved stability
    Patent number: 7205277
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: April 17, 2007
    Assignee: Sanofi-Aventis Deutschland Gmb
    Inventor: Peter Boderke
  • Zinc-free and low-zinc insulin preparations having improved stability
    Patent number: 7205276
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: April 17, 2007
    Assignee: Sanofi-Aventis Deutschland Gmb
    Inventor: Peter Boderke
  • Zinc-free and low-zinc insulin preparations having improved stability
    Patent number: 6960561
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: November 1, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Peter Boderke
  • Zinc-free and low-zinc insulin preparations having improved stability
    Publication number: 20050187142
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Application
    Filed: December 9, 2004
    Publication date: August 25, 2005
    Inventor: Peter Boderke
  • Zinc-free and low-zinc insulin preparations having improved stability
    Publication number: 20050187143
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Application
    Filed: December 9, 2004
    Publication date: August 25, 2005
    Inventor: Peter Boderke
  • Medicinal lipolysis of accumulations of fat
    Publication number: 20050143347
    Abstract: Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads.
    Type: Application
    Filed: December 14, 2004
    Publication date: June 30, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Peter Boderke, Matthias Gossel, Walter Kamm, Karl-Heinz Nietsch, Rainer Pooth, Juergen Sandow, Joerg Hager, Gerhard Sattler
  • Medicinal targeted local lipolysis
    Publication number: 20050089555
    Abstract: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.
    Type: Application
    Filed: October 21, 2004
    Publication date: April 28, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Peter Boderke, Rainer Pooth, Juergen Sandow, Matthias Gossel, Karl-Heinz Nietsch, Gerhard Sattler, Gerhard Vogel
  • Zinc-free and low-zinc insulin preparations having improved stability
    Publication number: 20030004096
    Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
    Type: Application
    Filed: March 22, 2002
    Publication date: January 2, 2003
    Inventor: Peter Boderke